Results 101 – 110 of 250 for Enhertu (0.04 seconds)

Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial

collaboration to jointly develop and commercialise Enhertu in March 2019 and datopotamab deruxtecan in July 2020, except in Japan where Daiichi Sankyo ...

Datopotamab deruxtecan plus Imfinzi demonstrated robust and durable tumour responses in 1st-line treatment of patients with metastatic triple-negative breast cancer in BEGONIA Phase Ib/II trial

collaboration to jointly develop and commercialise Enhertu in March 2019 and datopotamab deruxtecan in July 2020, except in Japan where Daiichi Sankyo ...

Statement on the passing of José Baselga

Daiichi-Sankyo in relation to the clinical development of Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan, two medicines which have ...

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

collaboration to jointly develop and commercialise Enhertu in March 2019 and datopotamab deruxtecan in July 2020, except in Japan where Daiichi Sankyo ...

Datroway (datopotamab deruxtecan) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

collaboration to jointly develop and commercialise Enhertu (trastuzumab deruxtecan) in March 2019 and Datroway in July 2020, except in Japan where ...

9M and Q3 2025 results

high-impact readouts for baxdrostat in hypertension and Enhertu and Datroway in breast cancer. We are also delivering on our strategy to strengthen ...

Q1 2025 results

recently the highly anticipated DESTINYBreast09 for Enhertu, as well as SERENA-6 for camizestrant and MATTERHORN for Imfinzi; the latter two of these ...

AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO

Presidential Symposium will feature DESTINY-Breast11 and DESTINY-Breast05, underscoring potential of Enhertu in HER2-positive early breast ...

AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024

setting, and data for datopotamab deruxtecan and Enhertu in several lung cancer settings will highlight how antibody drug conjugates have the ...

AstraZeneca aims to transform cancer treatment and advance clinical practice with data presented at ESMO 2020

DESTINY-Gastric01 Phase II trial will show the results of Enhertu (trastuzumab deruxtecan) in patients with metastatic gastric cancer and low ...

Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Next